Compare · MMM vs QNRX
MMM vs QNRX
Side-by-side comparison of 3M Company (MMM) and Quoin Pharmaceuticals Ltd. (QNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and QNRX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $82.25B, about 9681.6x QNRX ($8.5M).
- Over the past year, MMM is down 0.2% and QNRX is down 51.9% - MMM leads by 51.7 points.
- MMM has been more active in the news (7 items in the past 4 weeks vs 5 for QNRX).
- MMM has more recent analyst coverage (25 ratings vs 0 for QNRX).
- Company
- 3M Company
- Quoin Pharmaceuticals Ltd.
- Price
- $157.71+0.16%
- $4.28-6.24%
- Market cap
- $82.25B
- $8.5M
- 1M return
- +0.58%
- -14.57%
- 1Y return
- -0.22%
- -51.88%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 0
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Latest MMM
- 3M Announces Upcoming Investor Event
- 3M Young Scientist Challenge Names 10 Finalists for 2026 National Competition
- Group President Bauer Wendy A exercised 7,952 shares at a strike of $159.96 and covered exercise/tax liability with 3,558 shares, increasing direct ownership by 94% to 9,086 units (SEC Form 4)
- 3M and Discovery Education announce 37 State Merit Winners and four Honorable Mentions in 2026 3M Young Scientist Challenge
- 3M joins Cadillac Formula 1® Team as Official Material Science Partner to accelerate racing performance
- 3M and Airbus announce agreement to advance A220 passenger comfort and aircraft performance through advanced insulation technology
- 3M launches Ask 3M, an AI-powered tool for faster access to technical expertise
- Goldman resumed coverage on 3M with a new price target
- Bernstein initiated coverage on 3M with a new price target
- Director Rumsey Jennifer was granted 1,196 shares (SEC Form 4)
Latest QNRX
- Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
- SEC Form PRE 14A filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
- Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
- Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
- SEC Form SCHEDULE 13G filed by Quoin Pharmaceuticals Ltd.